MR spectroscopic evaluation of N-acetylaspartate's T2 relaxation time and concentration corroborates white matter abnormalities in schizophrenia

NeuroImage

Volumn 48, Issue 3, 2009, Pages 525-531

  Tunc Skarka, Nuran ^a   Weber Fahr, Wolfgang ^a   Hoerst, Mareen ^a   Meyer Lindenberg, Andreas ^a   Zink, Mathias ^a   Ende, Gabriele ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

1H MR spectroscopy; Absolute quantification; N acetylaspartate; Schizophrenia; T2 relaxation time

Indexed keywords

ARIPIPRAZOLE; N ACETYLASPARTIC ACID; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; BRAIN METABOLISM; BRAIN WATER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METABOLITE; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SCHIZOPHRENIA; WHITE MATTER;

ADULT; ANALYSIS OF VARIANCE; ASPARTIC ACID; CREATINE; DIPEPTIDES; FEMALE; FRONTAL LOBE; GLUTAMIC ACID; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NERVE FIBERS, MYELINATED; PHOSPHOCREATINE; PROTONS; SCHIZOPHRENIA; WATER;

EID: 69249217769     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.06.061     Document Type: Article

References (57)

1. Ashtari M., Cottone J., Ardekani B.A., Cervellione K., Szeszko P.R., Wu J., Chen S., and Kumra S. Disruption of white matter integrity in the inferior longitudinal fasciculus in adolescents with schizophrenia as revealed by fiber tractography. Arch. Gen. Psychiatry 64 (2007) 1270-1280
2. Aydin K., Ucok A., and Cakir S. Quantitative proton MR spectroscopy findings in the corpus callosum of patients with schizophrenia suggest callosal disconnection. AJNR Am. J. Neuroradiol. 28 (2007) 1968-1974
3. Aydin K., Ucok A., and Guler J. Altered metabolic integrity of corpus callosum among individuals at ultra high risk of schizophrenia and first-episode patients. Biol. Psychiatry 64 (2008) 750-757
4. Bagary M.S., Symms M.R., Barker G.J., Mutsatsa S.H., Joyce E.M., and Ron M.A. Gray and white matter brain abnormalities in first-episode schizophrenia inferred from magnetization transfer imaging. Arch. Gen. Psychiatry 60 (2003) 779-788
5. Bartha R., al-Semaan Y.M., Williamson P.C., Drost D.J., Malla A.K., Carr T.J., Densmore M., Canaran G., and Neufeld R.W. A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol. Psychiatry 45 (1999) 1403-1411
6. Baslow M.H. N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem. Res. 28 (2003) 941-953
7. Benes F.M., Vincent S.L., and Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol. Psychiatry 50 (2001) 395-406
8. Bertolino A., Sciota D., Brudaglio F., Altamura M., Blasi G., Bellomo A., Antonucci N., Callicott J.H., Goldberg T.E., Scarabino T., Weinberger D.R., and Nardini M. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am. J. Psychiatry 160 (2003) 483-489
9. Briellmann R.S., Jackson G.D., Pell G.S., Mitchell L.A., and Abbott D.F. Structural abnormalities remote from the seizure focus: a study using T2 relaxometry at 3 T. Neurology 63 (2004) 2303-2308
10. Buckley P.F., Moore C., Long H., Larkin C., Thompson P., Mulvany F., Redmond O., Stack J.P., Ennis J.T., and Waddington J.L. 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol. Psychiatry 36 (1994) 792-800
11. Buckley P., O'Callaghan E., Mulvany F., Larkin C., Stack J.P., Redmond O., Ennis J.T., Thompson P., and Waddington J.L. Basal ganglia T2 relaxation times in schizophrenia: a quantitative magnetic resonance imaging study in relation to tardive dyskinesia. Psychiatry Res. 61 (1995) 95-102
12. Callicott J.H., Bertolino A., Egan M.F., Mattay V.S., Langheim F.J., and Weinberger D.R. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry 157 (2000) 1646-1651
13. Chang L., Friedman J., Ernst T., Zhong K., Tsopelas N.D., and Davis K. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol. Psychiatry 62 (2007) 1396-1404
14. Choi C., Coupland N.J., Bhardwaj P.P., Kalra S., Casault C.A., Reid K., and Allen P.S. T2 measurement and quantification of glutamate in human brain in vivo. Magn. Reson. Med. 56 (2006) 971-977
15. Davis K.L., Stewart D.G., Friedman J.I., Buchsbaum M., Harvey P.D., Hof P.R., Buxbaum J., and Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch. Gen. Psychiatry 60 (2003) 443-456
16. Deicken R.F., Zhou L., Corwin F., Vinogradov S., and Weiner M.W. Decreased left frontal lobe N-acetylaspartate in schizophrenia. Am. J. Psychiatry 154 (1997) 688-690
17. Deicken R.F., Zhou L., Schuff N., and Weiner M.W. Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia. Schizophr. Res. 27 (1997) 65-71
18. Deicken R.F., Feiwell R., Schuff N., and Soher B. Evidence for altered cerebellar vermis neuronal integrity in schizophrenia. Psychiatry Res. 107 (2001) 125-134
19. Delamillieure P., Constans J.M., Fernandez J., Brazo P., Benali K., Courtheoux P., Thibaut F., Petit M., and Dollfus S. Proton magnetic resonance spectroscopy (1H MRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex. Schizophr. Bull. 28 (2002) 329-339
20. Ende G., Braus D.F., Walter S., Weber-Fahr W., Soher B., Maudsley A.A., and Henn F.A. Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophr. Res. 41 (2000) 389-395
21. Ende G., Braus D.F., Walter S., and Henn F.A. Lower concentration of thalamic n-acetylaspartate in patients with schizophrenia: a replication study. Am. J. Psychiatry 158 (2001) 1314-1316
22. Ende G., Braus D.F., Walter S., Weber-Fahr W., and Henn F.A. Multiregional 1H-MRSI of the hippocampus, thalamus, and basal ganglia in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 253 (2003) 9-15
23. Ende G., Hubrich P., Walter S., Weber-Fahr W., Kammerer N., Braus D.F., and Henn F.A. Further evidence for altered cerebellar neuronal integrity in schizophrenia. Am. J. Psychiatry 162 (2005) 790-792
24. Faustman W.O., Bardgett M., Faull K.F., Pfefferbaum A., and Csernansky J.G. Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol. Psychiatry 45 (1999) 68-75
25. Fields R.D. White matter in learning, cognition and psychiatric disorders. Trends Neurosci. 31 (2008) 361-370
26. Fields R.D. White matter matters. Sci. Am. 298 (2008) 42-49
27. Flynn S.W., Lang D.J., Mackay A.L., Goghari V., Vavasour I.M., Whittall K.P., Smith G.N., Arango V., Mann J.J., Dwork A.J., Falkai P., and Honer W.G. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol. Psychiatry 8 (2003) 811-820
28. Friedman S.D., Shaw D.W., Artru A.A., Dawson G., Petropoulos H., and Dager S.R. Gray and white matter brain chemistry in young children with autism. Arch. Gen. Psychiatry 63 (2006) 786-794
29. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., Haroutunian V., and Fienberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4746-4751
30. Hof P.R., Haroutunian V., Copland C., Davis K.L., and Buxbaum J.D. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem. Res. 27 (2002) 1193-1200
31. Jakary A., Vinogradov S., Feiwell R., and Deicken R.F. N-acetylaspartate reductions in the mediodorsal and anterior thalamus in men with schizophrenia verified by tissue volume corrected proton MRSI. Schizophr. Res. 76 (2005) 173-185
32. Karlsgodt K.H., van Erp T.G., Poldrack R.A., Bearden C.E., Nuechterlein K.H., and Cannon T.D. Diffusion tensor imaging of the superior longitudinal fasciculus and working memory in recent-onset schizophrenia. Biol. Psychiatry 63 (2008) 512-518
33. Katsel P., Davis K.L., Gorman J.M., and Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr. Res. 77 (2005) 241-252
34. Katsel P., Davis K.L., and Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr. Res. 79 (2005) 157-173
35. Katsel P., Davis K.L., Li C., Tan W., Greenstein E., Kleiner Hoffman L.B., and Haroutunian V. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology 33 (2008) 2993-3009
36. Kegeles L.S., Shungu D.C., Anjilvel S., Chan S., Ellis S.P., Xanthopoulos E., Malaspina D., Gorman J.M., Mann J.J., Laruelle M., and Kaufmann C.A. Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res. 98 (2000) 163-175
37. Kirov I.I., Fleysher L., Fleysher R., Patil V., Liu S., and Gonen O. Age dependence of regional proton metabolites T2 relaxation times in the human brain at 3 T. Magn. Reson. Med. 60 (2008) 790-795
38. Kubicki M., Park H., Westin C.F., Nestor P.G., Mulkern R.V., Maier S.E., Niznikiewicz M., Connor E.E., Levitt J.J., Frumin M., Kikinis R., Jolesz F.A., McCarley R.W., and Shenton M.E. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. NeuroImage 26 (2005) 1109-1118
39. Larvaron P., Bielicki G., Boespflug-Tanguy O., and Renou J.P. Proton MRS of early post-natal mouse brain modifications in vivo. NMR Biomed. 19 (2006) 180-187
40. Lim K.O., Adalsteinsson E., Spielman D., Sullivan E.V., Rosenbloom M.J., and Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch. Gen. Psychiatry 55 (1998) 346-352
41. Lim K.O., Hedehus M., Moseley M., de Crespigny A., Sullivan E.V., and Pfefferbaum A. Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. Arch. Gen. Psychiatry 56 (1999) 367-374
42. Maudsley A.A., Domenig C., Govind V., Darkazanli A., Studholme C., Arheart K., and Bloomer C. Mapping of brain metabolite distributions by volumetric proton MR spectroscopic imaging (MRSI). Magn. Reson. Med. 61 (2009) 548-559
43. Ongur D., Jensen J.E., Prescot A.P., Stork C., Lundy M., Cohen B.M., and Renshaw P.F. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol. Psychiatry 64 (2008) 718-726
44. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30 (1993) 672-679
45. Rajkowska G., Selemon L.D., and Goldman-Rakic P.S. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch. Gen. Psychiatry 55 (1998) 215-224
46. Rusch N., Tebartz van Elst L., Valerius G., Buchert M., Thiel T., Ebert D., Hennig J., and Olbrich H.M. Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr. Res. 99 (2008) 155-163
47. Schlosser R.G., Nenadic I., Wagner G., Gullmar D., von Consbruch K., Kohler S., Schultz C.C., Koch K., Fitzek C., Matthews P.M., Reichenbach J.R., and Sauer H. White matter abnormalities and brain activation in schizophrenia: a combined DTI and fMRI study. Schizophr. Res. 89 (2007) 1-11
48. Schubert F., Seifert F., Elster C., Link A., Walzel M., Mientus S., Haas J., and Rinneberg H. Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrations. Magma 14 (2002) 213-222
49. Schubert F., Gallinat J., Seifert F., and Rinneberg H. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. NeuroImage 21 (2004) 1762-1771
50. Selemon L.D., and Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry 45 (1999) 17-25
51. Soher B.J., Young K., Bernstein A., Aygula Z., and Maudsley A.A. GAVA: spectral simulation for in vivo MRS applications. J. Magn. Reson. 185 (2007) 291-299
52. Steen R.G., Hamer R.M., and Lieberman J.A. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 30 (2005) 1949-1962
53. Tanaka Y., Obata T., Sassa T., Yoshitome E., Asai Y., Ikehira H., Suhara T., Okubo Y., and Nishikawa T. Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction. Psychiatry Clin. Neurosci. 60 (2006) 365-372
54. Tkachev D., Mimmack M.L., Huffaker S.J., Ryan M., and Bahn S. Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int. J. Neuropsychopharmacol. 10 (2007) 557-563
55. Traber F., Block W., Lamerichs R., Gieseke J., and Schild H.H. 1H metabolite relaxation times at 3.0 Tesla: measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J. Magn. Reson. Imaging. 19 (2004) 537-545
56. Weber-Fahr W., Ende G., Braus D.F., Bachert P., Soher B.J., Henn F.A., and Buchel C. A fully automated method for tissue segmentation and CSF-correction of proton MRSI metabolites corroborates abnormal hippocampal NAA in schizophrenia. NeuroImage 16 (2002) 49-60
57. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 64 (2003) 663-667